- US-listed companies
- TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA
Market cap
$18.3B
P/E ratio
34.7x
| Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | |
| Net revenues | 16,121 | 18,312 | 20,317 | 20,314 | 20,272 | 19,652 | 21,903 | 22,385 | 18,854 | 16,887 | 16,659 | 15,878 | 14,925 | 15,846 |
| Cost of sales | 7,056 | 8,797 | 9,665 | 9,607 | 9,216 | 8,296 | 10,044 | 11,560 | 10,558 | 9,351 | 8,933 | 8,284 | 7,952 | 8,200 |
| Gross profit | 9,065 | 9,515 | 10,652 | 10,707 | 11,056 | 11,356 | 11,859 | 10,825 | 8,296 | 7,537 | 7,726 | 7,594 | 6,973 | 7,645 |
| Research and development expenses, net | 933 | 1,095 | 1,356 | 1,427 | 1,488 | 1,525 | 2,111 | 1,848 | 1,213 | 1,010 | 997 | 967 | 838 | 953 |
| Selling and Marketing Expense | 2,968 | 3,478 | 3,879 | 4,080 | 3,861 | 3,478 | 3,860 | 3,656 | 2,916 | 2,614 | 2,498 | 2,429 | 2,265 | 2,336 |
| General and Administrative Expense | 865 | 932 | 1,238 | 1,239 | 1,217 | 1,239 | 1,236 | 1,330 | 1,298 | 1,192 | 1,173 | 1,099 | 1,180 | 1,162 |
| Intangible assets impairments | - | - | - | - | - | - | - | - | 1,991 | 1,639 | 1,502 | 424 | 355 | 350 |
| Goodwill impairment | - | - | - | - | - | - | 900 | 17,100 | 3,027 | - | 4,628 | - | 2,045 | 700 |
| Impairments Restructuring And Others | - | - | - | 788 | 650 | 1,131 | 699 | 5,074 | 987 | 423 | 479 | 341 | 414 | 718 |
| Legal settlements and loss contingencies | - | - | - | 1,524 | -111 | 631 | 899 | 500 | -1,208 | 1,178 | 60 | 717 | 2,082 | 1,043 |
| Other income | - | - | - | - | - | - | - | - | - | 76 | 40 | 98 | 107 | 49 |
| Operating (loss) income | 3,871 | 3,109 | 2,205 | 1,649 | 3,951 | 3,352 | 2,154 | -17,484 | -1,637 | -443 | -3,572 | 1,716 | -2,099 | 433 |
| Financial expenses – net | -225 | -153 | -386 | -399 | -313 | -1,000 | -1,330 | -895 | -959 | -822 | -834 | -1,058 | -966 | -1,057 |
| Income (loss) before income taxes | 3,646 | 2,956 | 1,819 | 1,250 | 3,638 | 2,352 | 824 | -18,379 | -2,596 | -1,265 | -4,406 | 658 | -3,065 | -624 |
| Income taxes (benefit) | 283 | 127 | -137 | -43 | 591 | 634 | 521 | -1,933 | -195 | -278 | -168 | 211 | -638 | -7 |
| Share in (profits) losses of associated companies – net | -24 | -61 | -46 | -40 | -5 | -121 | 8 | -3 | -71 | -13 | 138 | 9 | 21 | 2 |
| Net income (loss) | 3,339 | 2,768 | 1,910 | 1,253 | 3,042 | 1,597 | 311 | -16,449 | -2,472 | -1,000 | -4,099 | 456 | -2,406 | -615 |
| Net Income (Loss) Attributable to Noncontrolling Interest | 8 | 9 | -53 | -16 | -13 | 9 | -18 | -184 | -322 | -2 | -109 | 39 | -53 | -56 |
| Net income (loss) attributable to Teva | 3,339 | 2,768 | 1,963 | 1,269 | 3,055 | 1,597 | 329 | -16,265 | -2,150 | -999 | -3,990 | 456 | -2,353 | -559 |
| Basic | 3.72 | 3.1 | 2.25 | 1.49 | 3.58 | 1.84 | 0.07 | -16.26 | -2.35 | -0.91 | -3.64 | 0.38 | -2.12 | -0.5 |
| Diluted | 3.67 | 3.09 | 2.25 | 1.49 | 3.56 | 1.82 | 0.07 | -16.26 | -2.35 | -0.91 | -3.64 | 0.38 | -2.12 | -0.5 |